SURMODICS INC Form 10-Q May 04, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837

Surmodics, Inc.

(Exact name of registrant as specified in its charter)

MINNESOTA 41-1356149 (State of incorporation) (I.R.S. Employer

Identification No.)

9924 West 74th Street

Eden Prairie, Minnesota 55344

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (952) 500-7000

Edgar Filing: SURMODICS INC - Form 10-Q

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer		Accelerated filer
Non-accelerated filer	(Do not check if a smaller reporting	Smaller reporting company
	company)	

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares of the registrant's Common Stock, \$.05 par value per share, outstanding as of May 2, 2018 was 13,257,956.

TABLE OF CONTENTS

<u>PART I.</u>	FINANCIAL INFORMATION	
Item 1.	Unaudited Condensed Financial Statements	3
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30
Item 4.	Controls and Procedures	30
PART II	. OTHER INFORMATION	
	Legal Proceedings	31
nem IA.	. <u>Risk Factors</u>	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31
Item 3.	Defaults Upon Senior Securities	31
Item 4.	Mine Safety Disclosures	31
Item 5.	Other Information	31
Item 6.	Exhibits	32

SIGNATURES 33

PART I. FINANCIAL INFORMATION

Item 1. Unaudited Condensed Financial Statements

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

	March	September	
	31,	30,	
	2018	2017	
(in thousands, except share and per share data)		(Unaudited)	
ASSETS			
Current Assets:			
Cash and cash equivalents	\$27,712	\$16,534	
Restricted cash	350		
Available-for-sale securities	38,330	31,802	
Accounts receivable, net of allowance for doubtful accounts of \$160 and \$230			
as of March 31, 2018 and September 30, 2017, respectively	7,216	7,211	
Inventories, net	4,046	3,516	
Income tax receivable	1,345	599	
Prepaids and other	2,342	1,221	
Total Current Assets	81,341	60,883	
Available-for-sale securities	3,953		
Deferred tax assets	3,326	4,027	
Property and equipment, net	25,844	22,942	
Intangible assets, net	19,725	20,562	
Goodwill	27,933	27,282	
Other assets	1,197	897	
Total Assets	\$163,319	\$136,593	
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current Liabilities:			
Accounts payable	\$2,012	\$2,396	
Accrued liabilities:	$\psi 2,012$	ψ2,390	
Compensation	3,859	3,822	
Accrued other	4,022	1,773	
Deferred revenue	4,022	62	
	12,097	02	

Contingent consideration